Pathway enrichment and FDA-approved drug repurposing analysis for the treatment of CTNNB1 Syndrome modeled in an SH-SY5Y cell line. Translation [Internet]. 2025 Oct. 15 [cited 2026 Jul. 27];14(S1). Available from: https://dev.openjournals.utoledo.edu/index.php/translation/article/view/1507